Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-17

Clinical Trial Update: Open-label Study of Dupilumab in Patients With Atopic Dermatitis [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial investigating dupilumab in patients with atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2023-10-17